Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway

British Journal of Pharmacology

Volumn 161, Issue 3, 2010, Pages 541-554

  Li, Feng ^a   Rajendran, Peramaiyan ^a   Sethi, Gautam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

multiple myeloma; proliferation; STAT3; thymoquinone

Indexed keywords

BORTEZOMIB; CYCLIN D1; INTERLEUKIN 6; JANUS KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE; PROTEIN MCL 1; PROTEIN TYROSINE PHOSPHATASE; STAT3 PROTEIN; SURVIVIN; THALIDOMIDE; THYMOQUINONE; VANADIC ACID; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; MULTIPLE MYELOMA; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PYRAZINES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THALIDOMIDE; VANADATES;

EID: 77956325713     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00874.x     Document Type: Article

References (76)

1. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB et al. (2006). Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091 : 151 169.
2. Aggarwal BB, Vijayalekshmi RV, Sung B (2009). Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15 : 425 430.
3. Badary OA (1999). Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol 67 : 135 142.
4. Badary OA, Gamal El-Din AM (2001). Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis. Cancer Detect Prev 25 : 362 368.
5. Badary OA, Al-Shabanah OA, Nagi MN, Al-Rikabi AC, Elmazar MM (1999). Inhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone. Eur J Cancer Prev 8 : 435 440.
6. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S et al. (2009). Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69 : 5575 5583.
7. Bharti AC, Donato N, Aggarwal BB (2003). Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171 : 3863 3871.
8. Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G et al. (2007). Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin Cancer Res 13 : 3024 3032.
9. Bowman T, Garcia R, Turkson J, Jove R (2000). STATs in oncogenesis. Oncogene 19 : 2474 2488.
10. Brierley MM, Fish EN (2005). Stats: multifaceted regulators of transcription. J Interferon Cytokine Res 25 : 733 744.
11. Campbell GS, Yu CL, Jove R, Carter-Su C (1997). Constitutive activation of JAK1 in Src-transformed cells. J Biol Chem 272 : 2591 2594.
12. Carballo M, Conde M, El Bekay R, Martin-Nieto J, Camacho MJ, Monteseirin J et al. (1999). Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes. J Biol Chem 274 : 17580 17586.
13. Cavo M (2006). Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20 : 1341 1352.
14. Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE et al. (2000). SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 275 : 27845 27850.
15. Chiarugi P, Cirri P, Marra F, Raugei G, Fiaschi T, Camici G et al. (1998). The Src and signal transducers and activators of transcription pathways as specific targets for low molecular weight phosphotyrosine-protein phosphatase in platelet-derived growth factor signaling. J Biol Chem 273 : 6776 6785.
16. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P et al. (1997a). Specific inhibition of Stat3 signal transduction by PIAS3. Science 278 : 1803 1805.
17. Chung J, Uchida E, Grammer TC, Blenis J (1997b). STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 17 : 6508 6516.
18. Costantino L, Barlocco D (2008). STAT 3 as a target for cancer drug discovery. Curr Med Chem 15 : 834 843.
19. Darnell JE Jr. (2002). Transcription factors as targets for cancer therapy. Nat Rev Cancer 2 : 740 749.
20. El-Dakhakhny M, Madi NJ, Lembert N, Ammon HP (2002). Nigella sativa oil, nigellone and derived thymoquinone inhibit synthesis of 5-lipoxygenase products in polymorphonuclear leukocytes from rats. J Ethnopharmacol 81 : 161 164.
21. El Gazzar M, El Mezayen R, Marecki JC, Nicolls MR, Canastar A, Dreskin SC (2006a). Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol 6 : 1135 1142.
22. El Gazzar M, El Mezayen R, Nicolls MR, Marecki JC, Dreskin SC (2006b). Downregulation of leukotriene biosynthesis by thymoquinone attenuates airway inflammation in a mouse model of allergic asthma. Biochim Biophys Acta 1760 : 1088 1095.
23. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA (2005). Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer 117 : 409 417.
24. El-Mahmoudy A, Matsuyama H, Borgan MA, Shimizu Y, El-Sayed MG, Minamoto N et al. (2002). Thymoquinone suppresses expression of inducible nitric oxide synthase in rat macrophages. Int Immunopharmacol 2 : 1603 1611.
25. El-Mahmoudy A, Shimizu Y, Shiina T, Matsuyama H, Nikami H, Takewaki T (2005). Macrophage-derived cytokine and nitric oxide profiles in type I and type II diabetes mellitus: effect of thymoquinone. Acta Diabetol 42 : 23 30.
26. El Mezayen R, El Gazzar M, Nicolls MR, Marecki JC, Dreskin SC, Nomiyama H (2006). Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation. Immunol Lett 106 : 72 81.
27. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K et al. (1997). A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387 : 921 924.
28. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R et al. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107 : 351 362.
29. Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A et al. (2004a). Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol 25 : 857 866.
30. Gali-Muhtasib HU, Abou Kheir WG, Kheir LA, Darwiche N, Crooks PA (2004b). Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs 15 : 389 399.
31. Gali-Muhtasib H, Roessner A, Schneider-Stock R (2006). Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol 38 : 1249 1253.
32. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA et al. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20 : 2499 2513.
33. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M et al. (2006). A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132 : 584 593.
34. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M et al. (2006). Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12 : 11 19.
35. Gunaje JJ, Bhat GJ (2001). Involvement of tyrosine phosphatase PTP1D in the inhibition of interleukin-6-induced Stat3 signaling by alpha-thrombin. Biochem Biophys Res Commun 288 : 252 257.
36. Han Y, Amin H, Franko B, Frantz C, Shi X, Lai R (2006). Loss of SHP1 enhances JAK3/STAT3 signalling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK-positive anaplastic large-cell lymphoma. Blood 108 : 2796 2803.
37. Ihle JN (1996). STATs: signal transducers and activators of transcription. Cell 84 : 331 334.
38. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G et al. (2001). CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409 : 349 354.
39. Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M et al. (2007). Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 67 : 7782 7788.
40. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K et al. (1988). Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332 : 83 85.
41. Kim H, Baumann H (1999). Dual signalling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol 19 : 5326 5338.
42. Klein B, Zhang XG, Lu ZY, Bataille R (1995). Interleukin-6 in human multiple myeloma. Blood 85 : 863 872.
43. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z et al. (2009). Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15 : 283 293.
44. Lufei C, Koh TH, Uchida T, Cao X (2007). Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity. Oncogene 26 : 7656 7664.
45. Mahgoub AA (2003). Thymoquinone protects against experimental colitis in rats. Toxicol Lett 143 : 133 143.
46. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ (1991). Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65 : 701 713.
47. Mohamed A, Shoker A, Bendjelloul F, Mare A, Alzrigh M, Benghuzzi H et al. (2003). Improvement of experimental allergic encephalomyelitis (EAE) by thymoquinone; an oxidative stress inhibitor. Biomed Sci Instrum 39 : 440 445.
48. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J et al. (2002). Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 : 2000 2008.
49. Ohtani T, Ishihara K, Atsumi T, Nishida K, Kaneko Y, Miyata T et al. (2000). Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 12 : 95 105.
50. Roepke M, Diestel A, Bajbouj K, Walluscheck D, Schonfeld P, Roessner A et al. (2007). Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther 6 : 160 169.
51. Salem ML (2005). Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol 5 : 1749 1770.
52. Schreiner SJ, Schiavone AP, Smithgall TE (2002). Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 277 : 45680 45687.
53. Servidei T, Aoki Y, Lewis SE, Symes A, Fink JS, Reeves SA (1998). Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2. J Biol Chem 273 : 6233 6241.
54. Sethi G, Ahn KS, Aggarwal BB (2008). Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res 6 : 1059 1070.
55. Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, Tithof PK (2003). In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol 22 : 107 113.
56. Simonian PL, Grillot DA, Nunez G (1997). Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 90 : 1208 1216.
57. Song JI, Grandis JR (2000). STAT signaling in head and neck cancer. Oncogene 19 : 2489 2495.
58. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ et al. (1997). A family of cytokine-inducible inhibitors of signalling. Nature 387 : 917 921.
59. Sun S, Steinberg BM (2002). PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells. J Gen Virol 83 (Pt 7 1651 1658.
60. Tanuma N, Nakamura K, Shima H, Kikuchi K (2000). Protein-tyrosine phosphatase PTPepsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells. J Biol Chem 275 : 28216 28221.
61. Tekeoglu I, Dogan A, Ediz L, Budancamanak M, Demirel A (2007). Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models. Phytother Res 21 : 895 897.
62. Tenev T, Bohmer SA, Kaufmann R, Frese S, Bittorf T, Beckers T et al. (2000). Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells. Eur J Cell Biol 79 : 261 271.
63. Tu Y, Renner S, Xu F, Fleishman A, Taylor J, Weisz J et al. (1998). BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 58 : 256 262.
64. Tu Y, Gardner A, Lichtenstein A (2000). The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 60 : 6763 6770.
65. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S et al. (2004). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10 : 48 54.
66. Woetmann A, Nielsen M, Christensen ST, Brockdorff J, Kaltoft K, Engel AM et al. (1999). Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci USA 96 : 10620 10625.
67. Worthen DR, Ghosheh OA, Crooks PA (1998). The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. Anticancer Res 18 (3A 1527 1532.
68. Yamamoto T, Sekine Y, Kashima K, Kubota A, Sato N, Aoki N et al. (2002). The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation. Biochem Biophys Res Commun 297 : 811 817.
69. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y et al. (2008). Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 7 : 1789 1796.
70. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE et al. (2001). SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28 : 29 35.
71. You M, Yu DH, Feng GS (1999). Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 19 : 2416 2424.
72. Yu H, Jove R (2004). The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4 : 97 105.
73. Yu Z, Zhang W, Kone BC (2002). Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J 367 (Pt 1 97 105.
74. Yue P, Turkson J (2009). Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18 : 45 56.
75. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N et al. (2002a). Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 168 : 466 474.
76. Zhang T, Seow KT, Ong CT, Cao X (2002b). Interdomain interaction of Stat3 regulates its Src homology 2 domain-mediated receptor binding activity. J Biol Chem 277 : 17556 17563.